Diamyd Medical contributes to JDRF initiative to increase understanding of type 1 diabetes

Print
| Source: Diamyd Medical AB (publ)
Diamyd Medical (Nasdaq Stockholm First North, Ticker: DMYD B) announced today
that the Company has joined a research initiative aimed at increasing the
understanding of the natural progression of type 1 diabetes in order to
transform and accelerate drug development for the disease. Diamyd Medical will
contribute data from the control (placebo) arm of its European Phase III study
with the diabetes vaccine Diamyd®. The data will be made available to the
research community in an open access database together with similar data from
other late stage studies in type 1 diabetes.
“Diamyd Medical’s contribution of high quality data to this project is of great
importance and they are a model company in doing so,” says Professor Mark
Atkinson, Director, Diabetes Institute, University of Florida, Gainesville, USA,
and one of the founders of the initiative. “It will allow the research community
to apply the principles of open science to decode this very complex disease.”

The project, funded by JDRF, aims to collect the C-peptide data over time from
the control or placebo arms of several late stage recent-onset type 1 diabetes
clinical trials conducted by industry and academia. The data will be made
available through a portal developed by Sage Bionetworks, a Seattle-based not
-for-profit research organization promoting open science. JDRF is funding this
effort to stimulate research to understand the pathogenesis of human type 1
diabetes and to design more effective, smaller and faster clinical trials.

“All stakeholders in the field of type 1 diabetes will benefit from combining
the dispersed individual pools of high quality clinical data that have been
collected in clinical trials,” says Professor Craig Beam, Department of
Biomedical Sciences, Western Michigan University Homer Stryker M.D. School of
Medicine, Kalamazoo, USA. “Having access to such large and complex human
datasets will allow the application of cutting-edge analytical methods to
developing approaches to optimize the design of recent-onset type 1 diabetes
clinical trials.”

The portal will become available in spring 2015.

About the diabetes vaccine Diamyd®
Type 1 diabetes is a devastating disease which requires daily treatment with
insulin to sustain life. The importance of finding a cure should not be
underestimated. Diamyd® is considered to be the world’s furthest developed
Antigen Based Therapy (ABT) for treating the disease. Diamyd® has been used in
clinical studies with more than 1,000 patients and has shown a good safety
profile. In a European Phase III study Diamyd® showed good clinical effect in
several subgroups, and a limited overall 16% efficacy (p=0.10) in preserving
endogenous insulin secretion. To enhance the overall effect, combination
treatments with Diamyd® and other approved agents are being pursued. Diamyd® is
easy to administer in any clinical setting. The potential annual market is
estimated to several billion dollars.

About Diamyd Medical
Diamyd Medical is dedicated to working toward a cure for type 1 diabetes and
LADA. The Company’s projects include development of combination regimens with
the GAD-based diabetes vaccine Diamyd® for arresting the destruction of insulin
-producing beta cells. The Company exclusively licenses UCLA-rights to GAD65,
the active ingredient in the vaccine, for which the last patent expires in 2032.
Additionally, the Company exclusively licenses UCLA patents for using GABA for
the treatment of diabetes and other inflammation-related conditions.

Diamyd Medical is one of the major shareholders in the stem cell company
Cellaviva AB, which is establishing a Swedish commercial bank for private family
saving of stem cells in umbilical cord blood and other sources of stem cells.
Stem cells can be expected to be used in Personalized Regenerative Medicine
(PRM), for example, to restore beta cell mass in diabetes patients where
autoimmunity has been arrested.

Remium Nordic AB is the Company’s Certified Adviser.
For further information, please contact:
Anders Essen-Möller, President and CEO
Phone: +46 70 55 10 679. E-mail: anders.essen-moller@diamyd.com
Diamyd Medical AB (publ)
Kungsgatan 29, SE-111 56 Stockholm, Sweden. Phone: +46 8 661 00 26, Fax: +46 8
661 63 68
E-mail: info@diamyd.com. Reg. no.: 556242-3797. Website: www.diamyd.com.